Cost-effectiveness analysis of prophylaxis therapies for invasive fungal infections following allogeneic haematopoietic stem cell transplantation in Mexico

2016 ◽  
Author(s):  
Claudie Charbonneau
Keyword(s):  
Stem Cell ◽  
Cost Effectiveness ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Fungal Infections ◽  
Cost Effectiveness Analysis ◽  
Invasive Fungal Infections ◽  
Haematopoietic Stem Cell ◽  
Effectiveness Analysis

scholarly journals COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

2015 ◽  
Vol 7 ◽  
pp. e2015048 ◽  
Author(s):  
Jean Elcheikh
Keyword(s):  
Stem Cell ◽  
Adverse Events ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Antifungal Therapy ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Haematopoietic Stem Cell ◽  
Serious Adverse Events ◽  
Hematopoietic Stem

Over the past decade, invasive fungal infections (IFI) have remained an important problem in patients undergoing allogeneic haematopoietic stem cell transplantation (Allo-HSCT). The optimal approach for prophylactic antifungal therapy has yet to be determined.We conducted a retrospective, bi-institutional comparative clinical study, and compared the efficacy and safety of micafungin 50mg/day (iv) with those of fluconazole (400mg/day) or itraconazole 200mg/day (iv) as prophylaxis for adult patients with various haematological diseases receiving haplo-identical allogeneic stem cell transplantation (haplo).Overall, 99 patients were identified; 30 patients received micafungin, and 69 patients received fluconazole or itraconazole. After a median follow-up of 13 months (range: 5-23), Proven or probable IFIs were reported in 3 patients (10%) in the micafungin group and 8 patients (12%) in the fluconazole or itraconazole group. Fewer patients in the micafungin group had invasive aspergillosis (1 [3%] vs. 5 [7%], P=0.6). A total of 4 (13%) patients in the micafungin group and 23 (33%) patients in the fluconazole or itraconazole group received empirical antifungal therapy (P = 0.14).No serious adverse events related to treatment were reported by patients and there was no treatment discontinuation because of drug-related adverse events in both groups.Despite the retrospective design of the study and limited sample, it contributes reassuring data to confirm results from randomised clinical trials, and to define a place for micafungin in prophylaxis after haplo.

Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma

2014 ◽  
Vol 28 (10) ◽  
pp. 1084-1091 ◽  
Author(s):  
Chintan Pandya ◽  
Shahrukh Hashmi ◽  
Nandita Khera ◽  
Morie A. Gertz ◽  
Angela Dispenzieri ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Cost Effectiveness ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document